Lenvatinib (LEN) is a first-line therapy for patients with hepatocellular carcinoma (HCC), but has a larger adverse effect profile. In this study, we developed a liposome with drug-carrying function and magnetic resonance imaging (MRI) imaging function to investigate the targeted drug-carrying function and MRI tracing ability of liposome for HCC.
Methods
Magnetic nano-liposomes (MNL) with dual targeting function of epithelial cell adhesion molecule (EpCAM) and vimentin and capable of encapsulating LEN drugs were prepared. The characterization performance, drug loading efficiency and cytotoxicity of EpCAM/vimentin-LEN-MNL were tested, and the dual-targeting slow release drug loading function and MRI tracing ability were investigated in cellular and animal models.
Results
EpCAM/vimentin-LEN-MNL has a mean particle size of 218.37 ± 5.13 nm and a mean potential of 32.86 ± 4.62 mV, and is spherical in shape and can be uniformly dispersed in solution. The encapsulation rate was 92.66 ± 0.73% and the drug loading rate was 9.35 ± 0.16%. It has low cytotoxicity, can effectively inhibit HCC cell proliferation and promote HCC cell apoptosis, and has specific targeting function and MRI tracing ability for HCC cells.
Conclusions
In this study, an HCC-specific dual-targeted sustained-release drug delivery liposome with dual-targeted recognition and sensitive MRI tracer was successfully prepared, which provides an important scientific basis for maximizing the multiple effects of nano-carriers in tumor diagnosis and treatment.
VogelAMeyerTSapisochinG, et al.Hepatocellular carcinoma. Lancet2022; 400(10360): 1345–1362.
2.
JohnsonPZhouQDaoDY, et al.Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol2022; 19(10): 670–681.
3.
KudoMFinnRSQinS, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet2018; 391(10126): 1163–1173.
4.
HuangMLongJYaoZ, et al.METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma. Cancer Res2023; 83(1): 89–102.
5.
PersoneniNPressianiTRimassaL. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma2019; 6: 31–39.
6.
ZhangYHuangHJinL, et al.Anticarcinogenic effects of isothiocyanates on hepatocellular carcinoma. Int J Mol Sci2022; 23(22): 13834.
7.
LuoJGaoBLinZ, et al.Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: a meta-analysis. Front Oncol2022; 12: 1010726.
8.
TouyzRMHerrmannSMSHerrmannJ. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens2018; 12(6): 409–425.
9.
LargeDEAbdelmessihRGFinkEA, et al.Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev2021; 176: 113851.
10.
ParkHOtteAParkK. Evolution of drug delivery systems: from 1950 to 2020 and beyond. J Control Release2022; 342: 53–65.
11.
LiuYCastro BravoKMLiuJ. Targeted liposomal drug delivery: a nanoscience and biophysical perspective. Nanoscale Horiz2021; 6(2): 78–94.
12.
AntimisiarisSGMaraziotiAKannavouM, et al.Overcoming barriers by local drug delivery with liposomes. Adv Drug Deliv Rev2021; 174: 53–86.
13.
SharmaACornejoCMihalicJ, et al.Physical characterization and in vivo organ distribution of coated iron oxide nanoparticles. Sci Rep2018; 8(1): 4916.
14.
PalanisamyWangSYM. Superparamagnetic iron oxide nanoparticulate system: synthesis, targeting, drug delivery and therapy in cancer. Dalton Trans2019; 48(26): 9490–9515.
15.
GuoLXiJTengJ, et al.Magnetic resonance neuroimaging contrast agents of nanomaterials. Biomed Res Int2022; 2022: 6790665.
16.
CaiZWuCYangL, et al.Assembly-controlled magnetic nanoparticle clusters as MRI contrast agents. ACS Biomater Sci Eng2020; 6(5): 2533–2542.
17.
MittalV. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol2018; 13: 395–412.
18.
QiLNXiangBDWuFX, et al.Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. Cancer Res2018; 78(16): 4731–4744.
19.
ZhangDYangLLiuX, et al.Hypoxia modulates stem cell properties and induces EMT through N-glycosylation of EpCAM in breast cancer cells. J Cell Physiol2020; 235(4): 3626–3633.
20.
SingalAGTayobNMehtaA, et al.GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology2022; 75(3): 541–549.
21.
MaraveliaPSilvaDNRovestiG, et al.Liquid biopsy in hepatocellular carcinoma: opportunities and challenges for immunotherapy. Cancers (Basel)2021; 13(17): 4334.
22.
ZhuYSTangKLvJ. Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci2021; 42(10): 857–869.
23.
HaoXGaiWWangL, et al.5-Boronopicolinic acid-functionalized polymeric nanoparticles for targeting drug delivery and enhanced tumor therapy. Mater Sci Eng C Mater Biol Appl2021; 119: 111553.
24.
SimonJSchwalmMMorsteinJ, et al.Mapping light distribution in tissue by using MRI-detectable photosensitive liposomes. Nat Biomed Eng2023; 7: 313–322.
25.
JinZYiXYangJ, et al.Liposome-coated arsenic-manganese complex for magnetic resonance imaging-guided synergistic therapy against carcinoma. Int J Nanomedicine2021; 16: 3775–3788.
26.
TenchovRBirdRCurtzeAE, et al.Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano2021; 15(11): 16982–17015.
27.
KimMLeeJSKimW, et al.Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. J Control Release2022; 348: 893–910.
28.
ZhouWMaXWangJ, et al.Co-delivery CPT and PTX prodrug with a photo/thermo-responsive nanoplatform for triple-negative breast cancer therapy. Smart Med2022; 1: e20220036.
29.
WangYMaXZhouW, et al.Reregulated mitochondrial dysfunction reverses cisplatin resistance microenvironment in colorectal cancer. Smart Med2022; 1: e20220013.
30.
WangJZhangLuXuCZ, et al.KRT17 serves as an oncogene biomarker of poor survival in patients with hepatocellular carcinoma. Biomed Tech2023; 3: 18–25.
31.
ZhangQKuangGZhangL, et al.Nanocarriers for platinum drug delivery. Biomed Tech2023; 2: 77–89.
32.
LiangYWangPYLiYJ, et al.Multistage O2-producing liposome for MRI-guided synergistic chemodynamic/chemotherapy to reverse cancer multidrug resistance. Int J Pharm2023; 631: 122488.
33.
ChenMXuXShuG, et al. Multifunctional microspheres dual-loaded with doxorubicin and sodium bicarbonate nanoparticles to introduce synergistic trimodal interventional therapy. ACS Appl Bio Mater2021; 4(4): 3476–3489.
34.
HaganAPhillipsGJMacfarlaneWM, et al.Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies. Eur J Pharm Sci2017; 101: 22–30.
35.
HuangZLLiFZhangJT, et al.Research on the construction of bispecific-targeted sustained-release drug-delivery microspheres and their function in treatment of hepatocellular carcinoma. ACS Omega2022; 7(25): 22003–22014.
36.
LeeKHLiapiEVossenJA, et al.Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol2008; 19(10): 1490–1496.
37.
MaXHWangSLiuSY, et al.Development and in vitro study of a bi-specific magnetic resonance imaging molecular probe for hepatocellular carcinoma. World J Gastroenterol2019; 25(24): 3030–3043.
38.
WangLShiYJiangJ, et al.Micro-nanocarriers based drug delivery technology for blood-brain barrier crossing and brain tumor targeting therapy. Small2022; 18(45): e2203678.
39.
YongTWeiZGanL, et al.Extracellular-vesicle-based drug delivery systems for enhanced antitumor therapies through modulating the cancer-immunity cycle. Adv Mater2022; 34(52): e2201054.
40.
ShiYvan der MeelRChenX, et al.The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics2020; 10(17): 7921–7924.
